MX2025002284A - Regímenes de dosificación de degradadores de receptores de estrógeno - Google Patents
Regímenes de dosificación de degradadores de receptores de estrógenoInfo
- Publication number
- MX2025002284A MX2025002284A MX2025002284A MX2025002284A MX2025002284A MX 2025002284 A MX2025002284 A MX 2025002284A MX 2025002284 A MX2025002284 A MX 2025002284A MX 2025002284 A MX2025002284 A MX 2025002284A MX 2025002284 A MX2025002284 A MX 2025002284A
- Authority
- MX
- Mexico
- Prior art keywords
- estrogen receptor
- dosage regimens
- receptor degraders
- degraders
- cdk4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se describen métodos para tratar el cáncer que comprenden administrar a un sujeto una dosis diaria del Compuesto A, o una sal farmacéuticamente aceptable de esta, en combinación con un inhibidor de CDK4/6.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263402651P | 2022-08-31 | 2022-08-31 | |
| US202363443892P | 2023-02-07 | 2023-02-07 | |
| US202363454422P | 2023-03-24 | 2023-03-24 | |
| US202363454485P | 2023-03-24 | 2023-03-24 | |
| US202363508503P | 2023-06-15 | 2023-06-15 | |
| PCT/US2023/031574 WO2024049926A1 (en) | 2022-08-31 | 2023-08-30 | Dosage regimens of estrogen receptor degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025002284A true MX2025002284A (es) | 2025-06-02 |
Family
ID=88192329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025002284A MX2025002284A (es) | 2022-08-31 | 2025-02-25 | Regímenes de dosificación de degradadores de receptores de estrógeno |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4580631A1 (es) |
| JP (1) | JP2025530742A (es) |
| KR (1) | KR20250076543A (es) |
| CN (1) | CN120112291A (es) |
| AU (1) | AU2023336057A1 (es) |
| CA (1) | CA3266061A1 (es) |
| IL (1) | IL319242A (es) |
| MX (1) | MX2025002284A (es) |
| TW (2) | TW202539669A (es) |
| WO (1) | WO2024049926A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CN119258223A (zh) * | 2023-07-06 | 2025-01-07 | 海创药业股份有限公司 | 一种降解雌激素受体的联合用药物及其用途 |
| WO2026044127A1 (en) * | 2024-08-22 | 2026-02-26 | Arvinas Operations, Inc. | Administration of cyp3a inhibitors in the treatment of cancer |
| WO2026128391A1 (en) * | 2024-12-09 | 2026-06-18 | Arvinas Operations, Inc. | Combinations of vepdegestrant and cdk4/6 inhibitors for treating esr1-mutant breast cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ534069A (en) | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
| DE602004017474D1 (de) | 2003-07-11 | 2008-12-11 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| KR20090052385A (ko) | 2006-09-08 | 2009-05-25 | 화이자 프로덕츠 인크. | 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온의합성 |
| AU2009284098B2 (en) | 2008-08-22 | 2012-03-29 | Astex Therapeutics Ltd. | Pyrrolopyrimidine compounds as CDK inhibitors |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
| DK3431475T3 (da) | 2013-02-21 | 2021-05-25 | Pfizer | Faste former af en selektiv CDK4/6-hæmmer |
| SI4197530T1 (sl) | 2015-04-16 | 2026-03-31 | Novartis Ag | Tableta ribocikliba |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| IL303143A (en) * | 2020-12-14 | 2023-07-01 | Arvinas Operations Inc | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
-
2023
- 2023-08-30 WO PCT/US2023/031574 patent/WO2024049926A1/en not_active Ceased
- 2023-08-30 CA CA3266061A patent/CA3266061A1/en active Pending
- 2023-08-30 CN CN202380075299.4A patent/CN120112291A/zh active Pending
- 2023-08-30 IL IL319242A patent/IL319242A/en unknown
- 2023-08-30 TW TW113146678A patent/TW202539669A/zh unknown
- 2023-08-30 AU AU2023336057A patent/AU2023336057A1/en active Pending
- 2023-08-30 KR KR1020257009876A patent/KR20250076543A/ko active Pending
- 2023-08-30 TW TW112132871A patent/TWI866427B/zh active
- 2023-08-30 JP JP2025512129A patent/JP2025530742A/ja active Pending
- 2023-08-30 EP EP23776753.8A patent/EP4580631A1/en active Pending
-
2025
- 2025-02-25 MX MX2025002284A patent/MX2025002284A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3266061A1 (en) | 2024-03-07 |
| AU2023336057A1 (en) | 2025-03-27 |
| IL319242A (en) | 2025-04-01 |
| EP4580631A1 (en) | 2025-07-09 |
| TW202416991A (zh) | 2024-05-01 |
| WO2024049926A1 (en) | 2024-03-07 |
| CN120112291A (zh) | 2025-06-06 |
| TW202539669A (zh) | 2025-10-16 |
| KR20250076543A (ko) | 2025-05-29 |
| TWI866427B (zh) | 2024-12-11 |
| JP2025530742A (ja) | 2025-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000105A (es) | Inhibidor de kras g12c para el tratamiento del cancer | |
| MX2022009044A (es) | Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina. | |
| PH12022553389A1 (en) | Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia | |
| TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| LU92642I2 (fr) | Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid) | |
| MXPA05012155A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades. | |
| RU2015107877A (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| MX2023013715A (es) | Regímenes de dosis de ecubectedina. | |
| MX2023007058A (es) | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. | |
| ZA202006072B (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| NZ718766A (en) | Anti-folr1 immunoconjugate dosing regimens | |
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| MX2025012780A (es) | Tratamiento de la psoriasis con un inhibidor de bajo peso molecular del factor de necrosis tumoral alfa | |
| MX2023000438A (es) | Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1. | |
| MX2022008216A (es) | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. | |
| MX2025001181A (es) | Regimenes de dosificacion que comprenden un inhibidor kat6 para el tratamiento de cancer | |
| MX2023009962A (es) | Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso. | |
| MX2022016410A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos. | |
| MX2023010394A (es) | Metodos para tratar el cancer usando una combinacion de regimenes de dosificacion de serd. | |
| BRPI1008000A2 (pt) | composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto. | |
| NZ587941A (en) | Methods to inhibit tumor cell growth by using lansoprazole | |
| MX2023005695A (es) | Administracion de agonista de sting, inhibidores de puntos de control y radiacion. |